Omniscient Neurotechnology (o8t)

Omniscient Neurotechnology (o8t) is a Sydney-based brain-mapping company that uses AI and machine learning to turn ordinary MRI scans into detailed maps of the brain's electrical networks, or connectomes. Its flagship FDA-cleared platform, Quicktome, gives neurosurgeons a patient-specific view of the pathways responsible for speech, movement and cognition before they operate, while its research platform, Infinitome, helps scientists study how diseases like Alzheimer's, epilepsy and schizophrenia disrupt brain connectivity. Founded in 2019 and led by CEO Stephen Scheeler, the company has raised roughly US$124 million to date and is expanding connectomics into stroke, movement disorders and brain-computer interfaces.